A selective kappa opioid receptor agonist in patients with notalgia paresthetica led to "modestly" greater improvements in itchiness over placebo, but was associated with adverse events, a randomized ...
STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback